Creator / Remedy Entertainment

Remedy Entertainment is a Video Game developing company in Finland. Remedy was founded in 1995 by demoscene members from groups such as Future Crew. The year after Remedy released its first game Death Rally, a top-down perspective racing shooter published by Apogee and distributed by GT Interactive Software. In 2001, Remedy released its second game Max Payne. The game is best known for its film noir influences and popularizing bullet time in video games. Remedy sold all the rights to Max Payne in 2002 to Take-Two Interactive for US$10 million and 969 932 shares of stock. The following year, a sequel to the franchise developed by Remedy and Rockstar Games was released. This would be Remedy's last Max Payne game, as Rockstar continued developing the franchise on its own.

Advertisement:

Remedy would later work on Quantum Break, which was announced during the Xbox One event on 21 May 2013. The game was released on April 5, 2016. During the development of Quantum Break, the CEO of Remedy, Matias Myllyrinne, and Oskari Häkkinen, the head of franchise development, departed from the company. Remedy later announced the formation of a new team and that they're working on two projects. The first being a partnership with Smilegate on CrossFire 2. The second being published by 505 Games, which revealed at E3 2018 to be Control.

Advertisement:

Games developed:

• Max Payne
• Max Payne 2: The Fall of Max Payne
• Alan Wake (PC, Xbox 360)
  • Alan Wake: The Signal (DLC)
  • Alan Wake: The Writer (DLC)
• Alan Wake's American Nightmare (PC, Xbox 360)
• Death Rally (PC)
  • Death Rally 2011 (Android, iPhone/iPod, PC)
• Quantum Break (PC, Xbox One)
• CrossFire 2
• Control (PC, Xbox One, PS4)

---

Tropes used in Remedy games

• Creator Thumbprint: All of their original full-length games beside Death Rally have been third-person shooters where the protagonist wears a dark jacket, usually leather, and has some kind of powers which involve time. As of E3 2018 Control seems to be headed in that direction too.

---